Publications by authors named "Samir Ambrale"
Article Synopsis
- The study aims to analyze the characteristics of rectal cancer survivors participating in SWOG S1820, which tests an intervention (AIMS-RC) for managing bowel dysfunction after treatment.* -
- Participants were selected based on specific criteria including their treatment history and age, with outcomes focusing on bowel function, quality of life, and symptom management motivations.* -
- The research successfully recruited 117 participants over 29 months, revealing that most had made dietary changes post-surgery and experienced significant bowel problems, highlighting the need for better management strategies.*
Article Synopsis
- A hospital modified its handoff software to allow continuous updates of overnight clinical activity, ensuring morning clinicians are informed about important events.
- Cross-covering residents entered safety concerns and clinical issues into the software, which generated reports sent to primary providers for review before their shifts started.
- This new communication system reduced morning sign-out duration and improved perceptions of patient safety and the quality of handoff information among residents.
Stromal or mesenchymal neoplasms affecting the gastrointestinal (GI) tract have undergone a remarkable evolution in how they are perceived, classified, approached, diagnosed and managed over the last 30 years. Gastrointestinal stromal tumors (GIST) account for approximately 1% to 3% of all malignant GI tumors. The clinical features can vary depending on the anatomic location, size and aggressiveness of the tumor.
View Article and Find Full Text PDFThe discovery of CD117 mutation in almost all gastrointestinal stromal tumors (GISTs) marked a milestone. Other spindle cell neoplasms arising from the GI tract including lipoma, schwannoma, hemangioma, leiomyoma, and leiomyosarcoma are typically CD117-negative. GIST research and clinical care now represent a paradigm of translating discoveries in the molecular pathogenesis of cancer into highly effective targeted therapies that selectively inhibit etiologic "driver" pathways, leading to dramatically improved clinical outcomes.
View Article and Find Full Text PDF